OPS
FATE icon

Orion Portfolio Solutions’s Fate Therapeutics FATE Stock Holding History

Orion Portfolio Solutions’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5
Closed – – 2020
2019
Q4 		$0 Buy
+5
New +$79 ﹤0.01% 1845

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Orion Portfolio Solutions's FATE Position: Q1 2020 in Review

Orion Portfolio Solutions sold out of Fate Therapeutics (FATE) in Q1 2020, closing a stake of 5 shares.

Orion Portfolio Solutions first reported a position in FATE in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 156 funds tracked by Wall St. Rank hold FATE as of Q1 2020.

  • Orion Portfolio Solutions reported no remaining Fate Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Orion Portfolio Solutions sold 5 Fate Therapeutics shares in Q1 2020.
  • Orion Portfolio Solutions first reported a position in Fate Therapeutics in Q4 2019 and held it in 1 quarter.
  • Orion Portfolio Solutions's Fate Therapeutics position peaked at $0 in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2020.

Based on Orion Portfolio Solutions's 13F filing for Q1 2020, filed 15 May 2020.